Establishing cost-effectiveness of genetic targeting of cancer therapies

Valesca Retel, E.J.Th. Rutgers, M.A. Joore, Willem H. van Harten

Research output: Contribution to journalArticleAcademicpeer-review

3 Downloads (Pure)

Abstract

The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to help decision-making in an uncertain time of development.
Original languageEnglish
Pages (from-to)28-31
JournalEuropean journal of oncology pharmacy
Volume5
Issue number1
Publication statusPublished - 2011
Externally publishedYes

Fingerprint

Dive into the research topics of 'Establishing cost-effectiveness of genetic targeting of cancer therapies'. Together they form a unique fingerprint.

Cite this